>

>

IVDR Technical Documentation: Annex II, III and XIII Explained

IVDR Technical Documentation: Annex II, III and XIII Explained

IVDR Technical Documentation: Annex II, III and XIII Explained

IVDR

Obodux Team

Obodux IVDR is coming soon. We're extending our EU MDR technical file platform to the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR). Join the early access list to be among the first IVD manufacturers to use it.

The IVDR has applied since 26 May 2022, and the transition periods for legacy devices are running out. Most IVDs now need a notified body for the first time, so manufacturers have to produce technical documentation and performance evidence to a standard the old Directive never asked for. This guide explains what the IVDR requires.

What IVDR technical documentation must contain

  • Technical documentation (Annex II): device description and specification, information supplied by the manufacturer, design and manufacturing information, the general safety and performance requirements checklist, benefit-risk analysis and risk management, and product verification and validation.

  • Post-market surveillance (Annex III): the PMS plan, plus the PMS report for Class A and B devices or the periodic safety update report (PSUR) for Class C and D devices.

  • Performance evaluation (Annex XIII): the performance evaluation plan and report, built on the three pillars the IVDR requires: scientific validity, analytical performance and clinical performance.

  • Post-market performance follow-up (PMPF): the plan and evaluation report that keep your performance evidence current.

IVDR classification at a glance

IVDR devices fall into four risk classes under the seven classification rules in Annex VIII.

  • Class A: lowest risk, such as general laboratory products and specimen receptacles. Only sterile Class A devices need a notified body.

  • Class B: devices not covered by another rule, including many routine laboratory tests.

  • Class C: higher individual or public health risk, for example companion diagnostics, genetic testing and many self-tests.

  • Class D: the highest risk, such as tests for transmissible agents in blood, tissues or organs for transfusion or transplantation.

Under the old Directive, most IVDs were self-declared. Under the IVDR most need a notified body, so the quality of your documentation now decides how fast you reach the market.

IVDR transition deadlines

Regulation (EU) 2024/1860 extended the transition for legacy devices. It applies only where the manufacturer had a quality management system in place by 26 May 2025, applied to a notified body by the date below, and signed a written agreement within four months of applying.

  • Class D, and devices with an IVDD certificate: notified body application by 26 May 2025; transition ends 31 December 2027

  • Class C: application by 26 May 2026; transition ends 31 December 2028

  • Class B and sterile Class A: application by 26 May 2027; transition ends 31 December 2029

New devices that weren't on the market under the old Directive, and non-sterile Class A devices, have had to comply with the IVDR since 26 May 2022. See our guide to MDR and IVDR transition deadlines.

What Obodux IVDR will do

Obodux IVDR will build your documentation section by section against IVDR Annex II and III, link every general safety and performance requirement to its evidence, and keep versions and approvals in one place. It shares the core platform our MDR customers already use, with new modules for the performance evaluation, PMPF and IVDR classification.

Frequently asked questions

When will Obodux IVDR be available?

It is in development now. Join the early access list and we will contact you as soon as it is ready.

What is the difference between MDR and IVDR technical documentation?

The structure in Annex II and III is very similar. The main difference is the evidence: the IVDR requires a performance evaluation covering scientific validity, analytical performance and clinical performance (Annex XIII), instead of the clinical evaluation used under the MDR.

Do all IVDs need a notified body under the IVDR?

No. Non-sterile Class A devices are self-declared. Sterile Class A devices and all Class B, C and D devices need a notified body.

Can I use Obodux now if I make both medical devices and IVDs?

Yes. EU MDR and UKCA are live today, and IVDR will sit on the same platform. Start with a free gap analysis or read our MDR Annex II and III checklist.

Ready to structure your technical documentation?

Ready to structure your technical documentation?

Obodux is a SaaS platform that streamlines medical device compliance. Using AI tools and a secure workspace, it helps prepare CE, UKCA, and global documentation faster, stay audit-ready, and launch products confidently.

Compliance Disclaimer: Obodux provides tools to assist with regulatory compliance but does not guarantee regulatory approval. Users remain responsible for ensuring their compliance with applicable regulations.

Cyber Essentials Certified

© 2026 Obodux. All rights reserved. Obodux is the MedTech compliance product from BORIS Software Ltd.

Obodux, a product of BORIS Software Ltd
Turing House, 120 Millshaw, Beeston, Leeds LS11 8LZ, United Kingdom
Tel: 03300 414880

Obodux is a SaaS platform that streamlines medical device compliance. Using AI tools and a secure workspace, it helps prepare CE, UKCA, and global documentation faster, stay audit-ready, and launch products confidently.

Compliance Disclaimer: Obodux provides tools to assist with regulatory compliance but does not guarantee regulatory approval. Users remain responsible for ensuring their compliance with applicable regulations.

Cyber Essentials Certified

© 2026 Obodux. All rights reserved. Obodux is the MedTech compliance product from BORIS Software Ltd.

Obodux, a product of BORIS Software Ltd
Turing House, 120 Millshaw, Beeston, Leeds LS11 8LZ, United Kingdom
Tel: 03300 414880

Obodux is a SaaS platform that streamlines medical device compliance. Using AI tools and a secure workspace, it helps prepare CE, UKCA, and global documentation faster, stay audit-ready, and launch products confidently.

Compliance Disclaimer: Obodux provides tools to assist with regulatory compliance but does not guarantee regulatory approval. Users remain responsible for ensuring their compliance with applicable regulations.

Cyber Essentials Certified

© 2026 Obodux. All rights reserved. Obodux is the MedTech compliance product from BORIS Software Ltd.

Obodux, a product of BORIS Software Ltd
Turing House, 120 Millshaw, Beeston, Leeds LS11 8LZ, United Kingdom
Tel: 03300 414880